US 7396839
Crystalline forms of gatifloxacin
granted A61PA61P31/00A61P31/04
Quick answer
US patent 7396839 (Crystalline forms of gatifloxacin) held by Teva Pharmaceuticals USA, Inc. expires Mon Jul 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.
Key facts
- Applicant
- Teva Pharmaceuticals USA, Inc.
- Grant date
- Tue Jul 08 2008 00:00:00 GMT+0000 (Coordinated Universal Time)
- Expiration
- Mon Jul 03 2028 00:00:00 GMT+0000 (Coordinated Universal Time)
- Claims
- 36
- CPC classes
- A61P, A61P31/00, A61P31/04